
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp's positive outlook is supported by its strong assumptions regarding the clinical activity of ABS-101, which could potentially increase the probability of success (POS) in ulcerative colitis (UC) and Crohn's disease (CD) to 15%. A favorable outcome in clinical trials could validate Absci's comprehensive platform and attract interest from large pharmaceutical companies, showcasing its potential for significant advancements in biologic drug development. Additionally, the ongoing collaboration expansion with Almirall illustrates Absci's capability in delivering innovative therapeutics and underscores its guidance of securing at least one partnership with large pharma by 2025.
Bears say
The financial analysis indicates a negative outlook on Absci Corp's stock primarily due to increased dilution resulting from a recent financing round, which has pressured the company's valuation. Additionally, the lack of standard of care (SOC) in the endometriosis treatment segment, particularly for non-hormonal options, further raises concerns about the company's market positioning and potential revenue generation. Overall, these factors contribute to a cautious assessment of Absci's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares